Legend Biotech Corporation Reports Reduced Losses in Q3

Written by Emily J. Thompson, Senior Investment Analyst

Source: NASDAQ.COM

Updated: Nov 12 2025

0mins

LEGN+0.43%

Should l Buy LEGN?

Source: NASDAQ.COM

Quarterly Loss: Legend Biotech Corporation reported a loss of -$39.69 million for the third quarter, an improvement from -$125.32 million in the same period last year.
Earnings Per Share: The company's earnings per share (EPS) were -$0.11, compared to -$0.34 in the previous year.
Adjusted Earnings: Excluding certain items, the adjusted earnings for the quarter were -$18.78 million, or -$0.05 per share.
Revenue Growth: Revenue increased by 70% to $272.33 million, up from $160.21 million in the prior year.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy LEGN?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on LEGN

Wall Street analysts forecast LEGN stock price to rise

11 Analyst Rating

10 Buy

1 Hold

0 Sell

Strong Buy

Current: 21.170

Low

48.00

Averages

68.10

High

90.00

Current: 21.170

Low

48.00

Averages

68.10

High

90.00

RBC Capital

Outperform

maintain

$66 -> $62

2026-03-11

Reason

RBC Capital

Price Target

$66 -> $62

AI Analysis

2026-03-11

maintain

Outperform

Reason

RBC Capital lowered the firm's price target on Legend Biotech to $62 from $66 and keeps an Outperform rating on the shares after its Q4 results. The firm sees a significant disconnect between the share price and the fundamentals of the business, the analyst tells investors in a research note. The management's execution on many aspects of the Carvykti opportunity has been strong, with impressive Overall Survival data, improving real-world safety, expanding manufacturing, and consistent double digit revenue growth, the firm adds.

Morgan Stanley

Overweight

maintain

$50 -> $49

2026-03-11

Reason

Morgan Stanley

Price Target

$50 -> $49

2026-03-11

maintain

Overweight

Reason

Morgan Stanley lowered the firm's price target on Legend Biotech to $49 from $50 and keeps an Overweight rating on the shares. The firm, which updated estimates following the company's Q4 report, awaits additional data from the CARTITUDE-5 study and the earlier-stage in vivo pipeline this year.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for LEGN

Unlock Now

About LEGN

Legend Biotech Corporation is a global biopharmaceutical company. The Company is engaged in the discovery, development, manufacturing and commercialization of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

SPDR S&P China ETF Analysts See 34.69% Upside

Apr 03 2026NASDAQ.COM

ETF Target Price Analysis: The SPDR S&P China ETF (GXC) has an implied analyst target price of $124.19 per unit, with a current trading price of $92.21, indicating a 34.69% upside potential that reflects market optimism about the ETF's future performance.
Stock Potential Unveiled: Legend Biotech Corp (LEGN) trades at $19.14, while analysts set a target price of $60.63, suggesting a remarkable 216.78% upside, highlighting the company's strong growth potential in the biotech sector.
Structure Therapeutics Outlook: Structure Therapeutics Inc (GPCR) is priced at $53.48, with an analyst target of $109.00, indicating a potential increase of 103.81%, showcasing market expectations for its innovative drug development.
Market Confidence in VNET: VNET Group Inc (VNET) currently trades at $8.19, with an analyst target price of $16.34, reflecting a 99.55% upside, which indicates investor confidence in its future performance.

Legend Biotech (LEGN) Q4 2025 Earnings Transcript

Apr 01 2026NASDAQ.COM

Legend Biotech (LEGN) Q4 2024 Earnings Transcript

Apr 01 2026NASDAQ.COM

Legend Biotech (LEGN) Q2 2025 Earnings Transcript

Apr 01 2026NASDAQ.COM

Legend Biotech (LEGN) Q1 2025 Earnings Transcript

Apr 01 2026NASDAQ.COM

Johnson & Johnson Divests from 3 Biotech Companies While Retaining Investments in Potential Acquisition Candidates

Mar 25 2026Barron's

Johnson & Johnson's Holdings Report: The company has restated its fourth-quarter holdings report, which was filed last week.
Exit from Biotechs: Johnson & Johnson has exited three biotech companies as part of its portfolio adjustments.
Retention of Stakes: Despite the exits, the company has retained its stakes in several rumored acquisition targets.
Strategic Moves: These actions indicate a strategic shift in Johnson & Johnson's investment approach within the biotech sector.

SPDR S&P China ETF Analysts See 34.69% Upside

Apr 03 2026NASDAQ.COM

ETF Target Price Analysis: The SPDR S&P China ETF (GXC) has an implied analyst target price of $124.19 per unit, with a current trading price of $92.21, indicating a 34.69% upside potential that reflects market optimism about the ETF's future performance.
Stock Potential Unveiled: Legend Biotech Corp (LEGN) trades at $19.14, while analysts set a target price of $60.63, suggesting a remarkable 216.78% upside, highlighting the company's strong growth potential in the biotech sector.
Structure Therapeutics Outlook: Structure Therapeutics Inc (GPCR) is priced at $53.48, with an analyst target of $109.00, indicating a potential increase of 103.81%, showcasing market expectations for its innovative drug development.
Market Confidence in VNET: VNET Group Inc (VNET) currently trades at $8.19, with an analyst target price of $16.34, reflecting a 99.55% upside, which indicates investor confidence in its future performance.

Legend Biotech (LEGN) Q4 2025 Earnings Transcript

Apr 01 2026NASDAQ.COM

Legend Biotech (LEGN) Q4 2024 Earnings Transcript

Apr 01 2026NASDAQ.COM

Legend Biotech (LEGN) Q2 2025 Earnings Transcript

Apr 01 2026NASDAQ.COM

Legend Biotech (LEGN) Q1 2025 Earnings Transcript

Apr 01 2026NASDAQ.COM

Johnson & Johnson Divests from 3 Biotech Companies While Retaining Investments in Potential Acquisition Candidates

Mar 25 2026Barron's

Johnson & Johnson's Holdings Report: The company has restated its fourth-quarter holdings report, which was filed last week.
Exit from Biotechs: Johnson & Johnson has exited three biotech companies as part of its portfolio adjustments.
Retention of Stakes: Despite the exits, the company has retained its stakes in several rumored acquisition targets.
Strategic Moves: These actions indicate a strategic shift in Johnson & Johnson's investment approach within the biotech sector.

GET FREE REAL TIME NOTIFICATIONS

Stock Monitor for LEGN?

Get Started Free

FREE STOCK RECOMMENDATIONS DAILY

Stock Bullish Tomorrow

Get Started Free

70% BACKTESTED ACCURACY!

Should I Buy LEGN?

Get Started Free